In a dialysis patient with heart failure with reduced ejection fraction who is already taking spironolactone, should the angiotensin receptor‑neprilysin inhibitor sacubitril/valsartan be administered only twice daily?

ARNI Dosing: Twice Daily Administration is Mandatory

Yes, sacubitril/valsartan (ARNI) must be administered twice daily—this is the only FDA-approved and evidence-based dosing regimen for this medication. There is no alternative once-daily formulation or dosing schedule supported by clinical evidence or regulatory approval.

FDA-Approved Dosing Schedule

The FDA label explicitly specifies twice-daily administration for all patient populations 1:

• Starting dose: 49/51 mg twice daily
• Target dose: 97/103 mg twice daily
• Titration: Double the dose every 2-4 weeks as tolerated

This twice-daily regimen was used in all landmark trials demonstrating mortality and morbidity benefits, and deviating from this schedule means using the medication outside its evidence base.

Special Considerations for Dialysis Patients

In your specific clinical scenario—a dialysis patient with HFrEF already on spironolactone—the twice-daily dosing remains essential, though dose adjustments may be necessary:

Starting Strategy

For dialysis patients, particularly those with hemodynamic concerns or concurrent spironolactone use, consider initiating at half the usual starting dose (24/26 mg twice daily) 1. This approach is FDA-supported for patients not previously on ACE inhibitors/ARBs or on low doses of these agents.

Evidence in Dialysis Populations

Recent real-world data demonstrates that sacubitril/valsartan is both feasible and beneficial in dialysis patients when dosed twice daily 2, 3, 4:

• A large comparative effectiveness study (n=2,868 matched pairs) showed reduced all-cause mortality (HR 0.82) and hospitalization (HR 0.86) in hemodialysis patients 2
• Critical finding: Only 14% of dialysis patients achieved the maximum 97/103 mg twice-daily dose, yet clinical benefits were still observed at lower doses 2
• Multiple case reports and small series confirm tolerability of doses ranging from 12/13 mg to 49/51 mg twice daily in dialysis patients 3, 4, 5

Practical Dosing Algorithm for Your Patient

1. Initiation: Start at 24/26 mg twice daily (given dialysis status and concurrent spironolactone)
2. Monitor closely: Check blood pressure, potassium, and symptoms before each dialysis session initially
3. Titrate cautiously: Increase to 49/51 mg twice daily after 2-4 weeks if tolerated
4. Target realistic goals: Aim for 49/51 mg twice daily as a practical target in dialysis patients; further titration to 97/103 mg twice daily only if hemodynamically stable

Critical Safety Points with Spironolactone

Hyperkalemia risk is actually lower with ARNI than with ACE inhibitors in dialysis patients (HR 0.71) 2, but vigilant monitoring remains essential when combined with spironolactone:

• Check potassium before each dialysis session during titration
• Consider reducing spironolactone dose if potassium >5.5 mEq/L
• Hypotension risk is similar to ACE inhibitors/ARBs 2

Why Twice-Daily Dosing Cannot Be Modified

The pharmacokinetics of sacubitril/valsartan require twice-daily administration to maintain therapeutic neprilysin inhibition and angiotensin receptor blockade throughout the 24-hour period. The drug was specifically formulated and studied with this regimen 6, 7, 8.

There is no evidence supporting once-daily dosing, and such use would be considered off-label with unknown efficacy and safety.

Bottom Line

Administer sacubitril/valsartan twice daily at all doses. In your dialysis patient on spironolactone, start at 24/26 mg twice daily, monitor potassium and blood pressure closely, and titrate to 49/51 mg twice daily as tolerated. The twice-daily schedule is non-negotiable for achieving the medication's intended therapeutic effects.